DCDaniel R. Calnan

Daniel R. Calnan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel R. Calnan has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Single-Center Randomized Controlled Trial of Middle Meningeal Artery Embolization for Chronic Subdural Hematoma

    by Armin D. Tavakkoli, Julio D. Montejo, Katelyn E. Salotto, Zabiullah Bajouri, William J. Smith, Caitlin A. Payne, James E. Lee, John H. Kanter, Imad S. Khan, Vyacheslav I. Makler, et al.

    Structured Background: Embolization of the middle meningeal artery (MMA) for the treatment of chronic subdural hematoma (cSDH) has gained increasing acceptance since the publication of several nonrandomized studies that appear to demonstrate a high level of efficacy for the procedure both when performed as an adjunct to patients undergoing surgical drainage and when performed in minimally symptomatic patients treated without surgical drainage. Methods: We conducted a single-center, randomized controlled trial (RCT) of MMA embolization in consecutive patients presenting to our hospital with cSDH from April 2020 to July 2023. Enrolled patients were randomized to standard of care (observation vs. surgical drainage per the treating neurosurgeon) or standard of care plus MMA embolization. The primary endpoint was the combined criteria of cSDH resolution (defined as < 5mm), resolution of clinical symptoms, no further intervention, and no major treatment-related complications. Results: In total, 190 patients were screened, 46 were enrolled/randomized, and 1 withdrew immediately after randomization but before treatment. Accrual was ended early due to diminished enrollment; 79% of the accrual goal was achieved. Of the 45 study patients, 40 had sufficient follow up for primary outcome analysis. The primary endpoint was met by 14/20 (70%) in the control group and 15/20 (75%) in the MMA embolization group, respectively, p=0.5. Conclusions: In this RCT, no significant difference was observed between standard of care and standard of care plus MMA embolization for cSDH. While the effect size appears to be smaller than that suggested by early case series, ongoing trials with greater statistical power may show benefit for the procedure. Previously presented in abstract form at: New England Neurosurgical Society (NENS) 2024 Meeting Key Messages: What is already known on this topic – Middle meningeal artery (MMA) embolization appears to be a safe and effective treatment for chronic subdural hematoma (cSDH), based on large case series. Randomized controlled trials of MMA embolization are just now being completed. What this study adds – This study found no significant difference in the primary endpoint within 1 year (resolution of cSDH defined as < 5mm, no return of clinical symptoms, no need for further intervention, and no major treatment-related complications). How this study might affect research, practice or policy – Further research, specifically RCTs with greater statistical power, are needed to better elucidate whether MMA embolization adds a statistically significant benefit to standard of care in cSDH.


  • Ischemic Stroke Occurs Less Frequently in Patients With COVID-19

    by Kimon Bekelis, Symeon Missios, Javaad Ahmad, Nicos Labropoulos, Clemens M. Schirmer, Daniel R. Calnan, Jonathan Skinner, Todd A. MacKenzie

    Background and Purpose: The impact of coronavirus disease 2019 (COVID-19) on the occurrence of ischemic stroke has been the subject of increased speculation but has not been confirmed in large observational studies. We investigated the association between COVID-19 and stroke. Methods: We performed a cross-sectional study involving patients discharged from a healthcare system in New York State, from January to April 2020. A mixed-effects logistic regression analysis and a propensity score–weighted analysis were used to control for confounders and investigate the association of COVID-19 with ischemic stroke. Similar techniques were used to detect the impact of concurrent COVID-19 infection on unfavorable outcomes for patients with stroke. Results: Among 24 808 discharges, 2513 (10.1%) were diagnosed with COVID-19, and 566 (0.2%) presented with acute ischemic stroke. Patients diagnosed with COVID-19 were at one-quarter the odds of stroke compared with other patients (odds ratio, 0.25 [95% CI, 0.16–0.40]). This association was consistent in all age groups. Our results were robust in sensitivity analyses, including propensity score–weighted regression models. In patients presenting with stroke, concurrent infection with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) was associated with higher case-fatality (odds ratio, 10.50 [95% CI, 3.54–31.18]) and a trend towards increased occurrence of discharge to rehabilitation (odds ratio, 2.45 [95% CI, 0.81–1.25]). Conclusions: Using a comprehensive cross-section of patients from a large NY-based healthcare system, we did not identify a positive association between ischemic stroke and COVID-19. However, patients with stroke with COVID-19 had worse outcomes compared with those without, with over a 9-fold increase in mortality. Although no definitive conclusions can be reached from our observational study, our data do not support the concerns for an epidemic of stroke in young adults with COVID-19.